Skip to main navigation

preloader

Overview
News & Events
- News Releases
- Events
Presentations
SEC Filings
Stock Info
Corporate Governance
Resources & Contact

News Releases

Year

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

June 7, 2021

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

June 4, 2021

Cullinan Oncology Announces Management Transition

May 21, 2021

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

May 19, 2021

Cullinan Oncology Reports First Quarter 2021 Financial Results

May 14, 2021

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

April 7, 2021

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

March 30, 2021

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

March 2, 2021

Cullinan Management, Inc. Announces Business Update

February 22, 2021

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 12, 2021

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Investor Tools

News & Events
- News Releases
- Events

Stock Info
- Stock Quote & Chart

Corporate Governance

Financials & Filings

IR Resources

Copyright © 2021 Cullinan Oncology, Inc.. All rights reserved

Site - Footer

Terms of Use/Privacy